Bioreactor cultivation of lung organoids from induced pluripotent stem cells shows comparable outcomes, indicating promise for cancer therapy analysis.
Introduction Human induced pluripotent stem cells (iPSCs) can be successfully differentiated into complex (three-dimensional) lung spheroids or organoids and have thus proven to be promising in vitro tools that provide a robust system for simulating lung disease and modeling drug response. We previously described a very simple and practical protocol for producing iPSC-derived lung organoids (iPSC-LuOrgs) in ultra-low attachment plates without relying on a gel-like extracellular matrix. Methods Here, we produced these organoids in a stirred-tank bioreactor equipped with a unique membrane stirrer and compared this type of up-scaled and more automated cultivation with the manual variant. Detailed morphological and molecular analyses, including single-cell RNA sequencing, of the differently generated LuOrgs were performed. Results Just like in the manual variant, using the bioreactor morphologically comparable lung organoids could be obtained that showed a very similar cellular composition. This type of generation can also be considered as animal-component-free production. Discussion These freely floating LuOrgs are now available in large numbers for the investigation of, for example, cancer therapy approaches as a new and patient-oriented in vitro platform.
No takes yet. Share an insight, caveat, or question.
Kroepel et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: